The validity of neoadjuvant chemotherapy with paclitaxel plus S-1 is not inferior to that of SOX regimen for locally advanced gastric cancer: an observational study

The validity of neoadjuvant chemotherapy with paclitaxel plus S-1 is not inferior to that of SOX regimen for locally advanced gastric cancer: an observational study

Abstract Background Paclitaxel plus S-1(PTXS) has shown definite efficacy for advanced gastric cancer. However, the efficacy and safety of this regimen in neoadjuvant setting for locally advanced gastric cancer (LAGC) are unclear. This study aimed to compare the efficacy of neoadjuvant chemotherapy...

Full description

Bibliographic Details
Main Authors: Chenghai Zhang, Binghong Wu, Hong Yang, Zhendan Yao, Nan Zhang, Fei Tan, Maoxing Liu, Kai Xu, Lei Chen, Jiadi Xing, Ming Cui, Xiangqian Su
Format: Article
Language:English
Published: BMC 2022-11-01
Series:BMC Cancer
Subjects:
Locally advanced gastric cancer
Neoadjuvant chemotherapy
Pathological response
Oxaliplatin
Paclitaxel
Online Access:https://doi.org/10.1186/s12885-022-10230-1

Internet

https://doi.org/10.1186/s12885-022-10230-1

Similar Items